Posted by Michael Wonder on 08 Aug 2022
Lilly's Taltz (ixekizumab) now available in new, citrate free formulation to reduce injection site pain for improved patient experience
8 August 2022 - Since the medicine's first approval in 2016, nearly 130,000 people in the U.S. have been treated with Taltz.
Eli Lilly announced today the availability of a new, citrate-free formulation of Taltz (ixekizumab) 80 mg/mL solution for injection. The new formulation, which was recently approved by the U.S. FDA in May 2022, includes the same active ingredient as the original formulation.
The new Taltz formulation significantly reduced injection site pain experienced by some people immediately following injection as shown by an 86% decrease in a visual analog scale of pain versus the original formulation.
